Victoria Socha

DocwireNews

Results of the MIRROR randomized controlled trial comparing cotherapy of pegloticase plus methotrexate (MTX) with pegloticase plus placebo found increased urate-lowering response rate with MTX versus placebo (71.0% vs 38.5% during month 5). Infusion reaction rate was also lower in patients in the pegloticase + MTX group compared with those in the placebo group (4% vs 31%).Gout is a common comorbidity in patients with chronic kidney disease (CKD). Methotrexate is used cautiously in patients with CKD, making the impact of pegloticase + MTX cotherapy of interest. During a poster session at the American Society of Nephrology Kidney Week 2022, Abdul A. Abdellatif, MD, and colleagues presented changes in estimated glomerular filtration rate (eGFR) among participants in the MIRROR trial. The poster was titled eGFR Changes in Uncontrolled Gout Patients Randomized to Receive Methotrexate or Placebo as Co-Therapy to Pegloticase: MIRROR RCT Findings.Uncontrolled gout was defined as serum uric acid &ge;7 mg/dL, urate-lowering therapy failure/intolerance, and &ge;1 gout symptom. Following a 2-week MTX tolerance test and a 4-week blinded MTX/placebo run-in, patients with uncontrolled gout were randomized 2:1 to receive pegloticase (infusion of 8 mg every 2 weeks) and blinded oral MTX (15 mg/week) or placebo (patients with eGFR &lt;40 mL/min/1.73 m2 were excluded).Baseline eGFR was measured prior to MTX exposure (week 6). Mean change from baseline in eGFR was assessed via treatment and baseline eGFR status (&lt;60 mL/min/1.73 m2 and &ge;60 mL/min/1.73 m2). Analyses were performed on all randomized patients (intent-to-treat).The pegloticase + MTX group included 100 patients. Mean age was 56 years, 91% were male, and mean eGFR was 68.9 mL/min/1.73 m2. The pegloticase + placebo group included 52 patients. Mean age was 53 years, 85% were male, and mean eGFR was 71.1 mL/min/1.73 m2.In both treatment groups, eGFR was stable during the MTX/placebo run-in and after initiation of pegloticase (day 1). At week 24, mean change in eGFR from baseline was +5.3 mL/min/1.73 m2 in the MTX group (n=70; 69 responders) and +4.3 mL/min/1.73 m2 in the placebo group (n=19; 19 responders). There was no difference in change from baseline in eGFR at week 24 between the eGFR &lt;60 mL/min/1.73 m2 and the &ge;60 mL/min/1.73 m2 groups in the MTX cohort (+4.1 mL/min/1.73 m2 and +6.3 mL/min/1.73 m2, respectively) or in the placebo group (+2.5 mL/min/1.73 m2 and +7.8 mL/min/1.73 m2, respectively) (both P&ge;.48).In summary, the researchers said, &ldquo;eGFR did not appear to decrease after oral MTX initiation when administered as cotherapy with pegloticase. This was true for patients with and without pretherapy eGFR &lt;60 mL/min/1.73 m2. These findings suggest MTX cotherapy did not negatively impact renal function in MIRROR RCT trial participants.&rdquo;Source: Abdellatif A, Botson JK, Obermeyer KL, LaMoreaux B, Marder BA. eGFR changes in uncontrolled gout patients randomized to receive methotrexate or placebo as co-therapy to pegloticase: MIRROR RCT findings. SA-PO898. Abstract of a poster presented at the American Society of Nephrology Kidney Week 2022; November 5, 2022; Orlando, Florida. Funding for this study was provided by Horizon Therapeutics.

Jayme Locke, MD, MPH

Joel M. Topf, MD, FACP

The Promise of Xenotransplantation

NKF Spring Clinical Meetings 2025

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Sacituzimab Govitecan Showed Modest Activity for CNS Metastases

Triple-Negative Breast Cancer

Latest News

Changes in Renal Function in MIRROR RCT Participants

ASN Kidney Week 2022

Results of the MIRROR randomized controlled trial comparing cotherapy of pegloticase plus methotrexate (MTX) with pegloticase plus placebo found increased urate-lowering ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe